Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 10/20 | 0.61 |
| ▸ | PDE7B | Q9NP56 | 5/20 | 0.61 |
| ▸ | PDE8A | O60658 | 3/20 | 0.53 |
| ▸ | PDE1A | P54750 | 5/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837823 | 1.00 | PDE7A (0.61) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL135704 | 0.87 | PDE7A (0.58) | PDE7APDE7BPDE8ASIGMAR1JAK2 | |
| SCHEMBL582861 | 0.86 | PDE7A (0.57) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL30837940 | 0.86 | PDE7A (0.60) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL30837828 | 0.86 | PDE7A (0.59) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL581703 | 0.86 | PDE7A (0.60) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL32681343 | 0.86 | PDE7A (0.57) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL582178 | 0.86 | PDE7A (0.57) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL32681329 | 0.86 | PDE7A (0.57) | PDE7APDE7BPDE8APDE1APDE1C | |
| SCHEMBL582878 | 0.86 | PDE7A (0.57) | PDE7APDE7BPDE8APDE1APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | claimed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-8722659-B2 | Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | SANOFI (FR) | 2012-05-10 | — | — | US | disclosed |
| EP-2417130-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI (FR) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010116088-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | PDE7A 5/4885PDE7B 14/4885PDE8A 8/4885 |
| US-20120115846-A1 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF. | CYP27B1, NDUFB3, MT-ND5 | PDE7A 1134/4885PDE7B 1030/4885PDE8A 3030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.